Search clinical trials for: MK0999

Total 99 results

Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Migraine
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

Pulmonary Disease, Chronic Obstructive
Merck Sharp & Dohme LLC

Completed

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Diabetes Mellitus, Type 2 | Metabolic Syndrome
Merck Sharp & Dohme LLC

Completed

Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)

Migraine
Merck Sharp & Dohme LLC

Completed

Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

Migraine
Merck Sharp & Dohme LLC

Completed

Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Post-Menopausal Osteoporosis
Vyne Therapeutics Inc.

Completed

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Overactive Bladder | Urinary Incontinence
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)

Rheumatoid Arthritis
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Completed

A Study of MK0359 in Patients With Chronic Asthma (0359-013)

Asthma
Merck Sharp & Dohme LLC

Terminated

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Obesity
Vyne Therapeutics Inc.

Terminated

A Study of MK0594 in Patients With Alcohol Dependence (0594-020)

Alcohol Dependence
Merck Sharp & Dohme LLC

Completed

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Terminated

Dose-Range Finding Study for MK0893 (0893-008)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

Prostatic Neoplasms
H. Lundbeck A/S

Terminated

Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)

Candidiasis
Merck Sharp & Dohme LLC

Completed

Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Candidiasis | Aspergillosis
Merck Sharp & Dohme LLC

Completed

Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)

Candidiasis
Merck Sharp & Dohme LLC

Completed

A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Ambulatory Blood Pressure
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Neutropenia | Fever
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)

Coronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Merck Sharp & Dohme LLC

Completed

A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Migraine
H. Lundbeck A/S

Completed

Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)

Insomnia
Merck Sharp & Dohme LLC

Completed

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Hypertension
Merck Sharp & Dohme LLC

Completed

MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

Aspergillosis
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Antihypertensive Efficacy of MK0954

Hypertension
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Major Depressive Disorder
H. Lundbeck A/S

Completed

An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)

Insomnia
H. Lundbeck A/S

Withdrawn

An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)

Insomnia
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
University of Pavia

Enrolling by invitation

Influence of Different Nanohybrid Flowable Composite Resin on Shear Bond Strength and Dimensional Changes of Invisalign Attachments After 6 Months of Brushing

Malocclusion

Italy
Organon and Co

Terminated

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

Hypertension
Merck Sharp & Dohme LLC

Completed

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Dyslipidemia

3

Subscribe